Core Viewpoint - Amicus Therapeutics has been upgraded to a Buy rating from Hold by Needham, with a target price of $14, highlighting the undervaluation of its kidney disease program, DMX-200 [2] Summary by Category Company Performance - The stock of Amicus Therapeutics is up approximately 5% following the upgrade [2] Product Development - DMX-200 is currently in Phase trials, indicating ongoing development in the kidney disease program [2]